A COMPARATIVE CLINICAL STUDY OF EFFICACY OF RASNADYA GUGGULU AND SHIRASHULADIVAJRA RASA VATI IN THE MANAGEMENT OF ARDHAVABHEDAKA W.S.R. TO MIGRAINE

Background: Ardhavabhedaka, a Vata-pradhana Shiroroga described in Ayurveda, closely resembles migraine and is characterized by recurrent unilateral headache with associated symptoms such as nausea, vomiting, and aura. Conventional treatments provide symptomatic relief but often have adverse effects, highlighting the need for safer Ayurvedic alternatives. Aim: To evaluate and compare the efficacy of Rasnadyaguggulu and Shirashuladivajra Rasa Vati in the management of Ardhavabhedaka (migraine). Materials and Methods: A prospective comparative clinical study was conducted on 40 patients of Ardhavabhedaka, randomly divided into two groups. Group A received Rasnadyaguggulu 500 mg twice daily with Ushna Jala, and Group B received Shirashuladivajra Rasa Vati 1 g twice daily with honey for 30 days. Assessment was done using headache severity, frequency, duration, associated symptoms, and MIDAS score. Statistical analysis was performed using paired and unpaired t-tests. Results: Both groups showed significant improvement. Rasnadyaguggulu showed greater improvement in headache severity (62.96%), duration (55.66%), vomiting (78.12%) and MIDAS score (63.63%), while Shirashuladivajra Rasa Vati showed marked reduction in headache frequency (88.8%). Overall improvement was higher in Group A (54.22%) than Group B (45.72%). Conclusion: Both formulations are effective in Ardhavabhedaka, but Rasnadyaguggulu showed comparatively better clinical efficacy in reducing headache severity, duration and associated symptoms.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-03-16
DOI
https://doi.org/10.5281/zenodo.19043769
Primary Topic
Medical Case Reports and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A COMPARATIVE CLINICAL STUDY OF EFFICACY OF RASNADYA GUGGULU AND SHIRASHULADIVAJRA RASA VATI IN THE MANAGEMENT OF ARDHAVABHEDAKA W.S.R. TO MIGRAINE

Dr. Haloli Mahesh Sidramappa*1, Dr. Shiva Kumar C. Sarvi2, Dr. T. V. Halagatt3
Zenodo (CERN European Organization for Nuclear Research)
Medical Case Reports and Studies
article

A COMPARATIVE CLINICAL STUDY OF EFFICACY OF RASNADYA GUGGULU AND SHIRASHULADIVAJRA RASA VATI IN THE MANAGEMENT OF ARDHAVABHEDAKA W.S.R. TO MIGRAINE

Dr. Haloli Mahesh Sidramappa*1, Dr. Shiva Kumar C. Sarvi2, Dr. T. V. Halagatt3
article en

Abstract

Background: Ardhavabhedaka, a Vata-pradhana Shiroroga described in Ayurveda, closely resembles migraine and is characterized by recurrent unilateral headache with associated symptoms such as nausea, vomiting, and aura. Conventional treatments provide symptomatic relief but often have adverse effects, highlighting the need for safer Ayurvedic alternatives. Aim: To evaluate and compare the efficacy of Rasnadyaguggulu and Shirashuladivajra Rasa Vati in the management of Ardhavabhedaka (migraine). Materials and Methods: A prospective comparative clinical study was conducted on 40 patients of Ardhavabhedaka, randomly divided into two groups. Group A received Rasnadyaguggulu 500 mg twice daily with Ushna Jala, and Group B received Shirashuladivajra Rasa Vati 1 g twice daily with honey for 30 days. Assessment was done using headache severity, frequency, duration, associated symptoms, and MIDAS score. Statistical analysis was performed using paired and unpaired t-tests. Results: Both groups showed significant improvement. Rasnadyaguggulu showed greater improvement in headache severity (62.96%), duration (55.66%), vomiting (78.12%) and MIDAS score (63.63%), while Shirashuladivajra Rasa Vati showed marked reduction in headache frequency (88.8%). Overall improvement was higher in Group A (54.22%) than Group B (45.72%). Conclusion: Both formulations are effective in Ardhavabhedaka, but Rasnadyaguggulu showed comparatively better clinical efficacy in reducing headache severity, duration and associated symptoms.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 21%
Medical Case Reports and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.